ParkinsonCanadaV1, Main, Exploration, bibRecord, 003946

Prospects for new drug treatment in idiopathic parkinsonism

Identifieur interne : 003946 ( Main/Exploration ); précédent : 003945; suivant : 003947

Prospects for new drug treatment in idiopathic parkinsonism

Auteurs : Ali Samii [Canada] ; Shallen R. Letwin [Canada] ; Donald B. Calne [Canada]

Source :

Drug Discovery Today [ 1359-6446 ] ; 1998.

RBID : ISTEX:A1162F4C7AF034526D6951D547186E66B6F4C984

Descripteurs français

Pascal (Inist)
- Agoniste, Amine oxidase (flavin-containing), Antidépresseur, Antiparkinsonien, Catechol O-methyltransferase, Catécholamine, Dopamine, Entacapone, Essai clinique, Homme, Inhibiteur enzyme, Mécanisme action, Parkinson maladie, Parkinsonisme, Randomisation, Tolcapone, Toxicité, Trouble psychiatrique.
Wicri :
- topic : Homme.

English descriptors

KwdEn :
- Agonist, Amine oxidase (flavin-containing), Antidepressant agent, Antiparkinson agent, Catechol O-methyltransferase, Catecholamine, Clinical trial, Dopamine, Entacapone, Enzyme inhibitor, Human, Mechanism of action, Mental disorder, Parkinson disease, Parkinsonism, Randomization, Tolcapone, Toxicity.

Abstract

Parkinson's disease is one of the most common neurological disorders of the elderly. However, several recent drug developments have been made in the treatment of idiopathic parkinsonism (IP). The authors describe the most promising new drugs for treatment of the motor symptoms of IP, briefly discuss two promising monoamine oxidase inhibitors and review the newer medications for the treatment of the psychiatric symptoms associated with IP. They also survey some of the future therapeutic options in early stages of development.

Url:

https://api-v5.istex.fr/document/A1162F4C7AF034526D6951D547186E66B6F4C984/fulltext/pdf

DOI: 10.1016/S1359-6446(97)01158-6

Affiliations:

Canada

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Prospects for new drug treatment in idiopathic parkinsonism</title>
<author><name sortKey="Samii, Ali" sort="Samii, Ali" uniqKey="Samii A" first="Ali" last="Samii">Ali Samii</name>
</author>
<author><name sortKey="Letwin, Shallen R" sort="Letwin, Shallen R" uniqKey="Letwin S" first="Shallen R." last="Letwin">Shallen R. Letwin</name>
</author>
<author><name sortKey="Calne, Donald B" sort="Calne, Donald B" uniqKey="Calne D" first="Donald B." last="Calne">Donald B. Calne</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:A1162F4C7AF034526D6951D547186E66B6F4C984</idno>
<date when="1998" year="1998">1998</date>
<idno type="doi">10.1016/S1359-6446(97)01158-6</idno>
<idno type="url">https://api-v5.istex.fr/document/A1162F4C7AF034526D6951D547186E66B6F4C984/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000A08</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000A08</idno>
<idno type="wicri:Area/Istex/Curation">000A08</idno>
<idno type="wicri:Area/Istex/Checkpoint">001504</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">001504</idno>
<idno type="wicri:doubleKey">1359-6446:1998:Samii A:prospects:for:new</idno>
<idno type="wicri:Area/Main/Merge">003F61</idno>
<idno type="wicri:source">INIST</idno>
<idno type="RBID">Pascal:98-0168170</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000E33</idno>
<idno type="wicri:Area/PascalFrancis/Curation">001090</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000C90</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000C90</idno>
<idno type="wicri:doubleKey">1359-6446:1998:Samii A:prospects:for:new</idno>
<idno type="wicri:Area/Main/Merge">004040</idno>
<idno type="wicri:Area/Main/Curation">003946</idno>
<idno type="wicri:Area/Main/Exploration">003946</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Prospects for new drug treatment in idiopathic parkinsonism</title>
<author><name sortKey="Samii, Ali" sort="Samii, Ali" uniqKey="Samii A" first="Ali" last="Samii">Ali Samii</name>
<affiliation wicri:level="1"><country>Canada</country>
<wicri:regionArea>Neurodegenerative Disorders Centre, Vancouver Hospital and Health Sciences Centre, Purdy Pavilion, 2221 Wesbrook Mall, Vancouver, British Columbia</wicri:regionArea>
<wicri:noRegion>British Columbia</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Letwin, Shallen R" sort="Letwin, Shallen R" uniqKey="Letwin S" first="Shallen R." last="Letwin">Shallen R. Letwin</name>
<affiliation wicri:level="1"><country>Canada</country>
<wicri:regionArea>Neurodegenerative Disorders Centre, Vancouver Hospital and Health Sciences Centre, Purdy Pavilion, 2221 Wesbrook Mall, Vancouver, British Columbia</wicri:regionArea>
<wicri:noRegion>British Columbia</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Calne, Donald B" sort="Calne, Donald B" uniqKey="Calne D" first="Donald B." last="Calne">Donald B. Calne</name>
<affiliation wicri:level="1"><country>Canada</country>
<wicri:regionArea>Neurodegenerative Disorders Centre, Vancouver Hospital and Health Sciences Centre, Purdy Pavilion, 2221 Wesbrook Mall, Vancouver, British Columbia</wicri:regionArea>
<wicri:noRegion>British Columbia</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><country wicri:rule="url">Canada</country>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Drug Discovery Today</title>
<title level="j" type="abbrev">DRUDIS</title>
<idno type="ISSN">1359-6446</idno>
<imprint><publisher>ELSEVIER</publisher>
<date type="published" when="1998">1998</date>
<biblScope unit="volume">3</biblScope>
<biblScope unit="issue">3</biblScope>
<biblScope unit="page" from="131">131</biblScope>
<biblScope unit="page" to="140">140</biblScope>
</imprint>
<idno type="ISSN">1359-6446</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">1359-6446</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Agonist</term>
<term>Amine oxidase (flavin-containing)</term>
<term>Antidepressant agent</term>
<term>Antiparkinson agent</term>
<term>Catechol O-methyltransferase</term>
<term>Catecholamine</term>
<term>Clinical trial</term>
<term>Dopamine</term>
<term>Entacapone</term>
<term>Enzyme inhibitor</term>
<term>Human</term>
<term>Mechanism of action</term>
<term>Mental disorder</term>
<term>Parkinson disease</term>
<term>Parkinsonism</term>
<term>Randomization</term>
<term>Tolcapone</term>
<term>Toxicity</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Agoniste</term>
<term>Amine oxidase (flavin-containing)</term>
<term>Antidépresseur</term>
<term>Antiparkinsonien</term>
<term>Catechol O-methyltransferase</term>
<term>Catécholamine</term>
<term>Dopamine</term>
<term>Entacapone</term>
<term>Essai clinique</term>
<term>Homme</term>
<term>Inhibiteur enzyme</term>
<term>Mécanisme action</term>
<term>Parkinson maladie</term>
<term>Parkinsonisme</term>
<term>Randomisation</term>
<term>Tolcapone</term>
<term>Toxicité</term>
<term>Trouble psychiatrique</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Parkinson's disease is one of the most common neurological disorders of the elderly. However, several recent drug developments have been made in the treatment of idiopathic parkinsonism (IP). The authors describe the most promising new drugs for treatment of the motor symptoms of IP, briefly discuss two promising monoamine oxidase inhibitors and review the newer medications for the treatment of the psychiatric symptoms associated with IP. They also survey some of the future therapeutic options in early stages of development.</div>
</front>
</TEI>
<affiliations><list><country><li>Canada</li>
</country>
</list>
<tree><country name="Canada"><noRegion><name sortKey="Samii, Ali" sort="Samii, Ali" uniqKey="Samii A" first="Ali" last="Samii">Ali Samii</name>
</noRegion>
<name sortKey="Calne, Donald B" sort="Calne, Donald B" uniqKey="Calne D" first="Donald B." last="Calne">Donald B. Calne</name>
<name sortKey="Calne, Donald B" sort="Calne, Donald B" uniqKey="Calne D" first="Donald B." last="Calne">Donald B. Calne</name>
<name sortKey="Letwin, Shallen R" sort="Letwin, Shallen R" uniqKey="Letwin S" first="Shallen R." last="Letwin">Shallen R. Letwin</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003946 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003946 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:A1162F4C7AF034526D6951D547186E66B6F4C984
   |texte=   Prospects for new drug treatment in idiopathic parkinsonism
}}

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022

La maladie de Parkinson au Canada (serveur d'exploration)

Prospects for new drug treatment in idiopathic parkinsonism

Prospects for new drug treatment in idiopathic parkinsonism

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	La maladie de Parkinson au Canada (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.